MXPA06015096A - Composiciones y metodos para el tratamiento de trastornos neurologicos. - Google Patents

Composiciones y metodos para el tratamiento de trastornos neurologicos.

Info

Publication number
MXPA06015096A
MXPA06015096A MXPA06015096A MXPA06015096A MXPA06015096A MX PA06015096 A MXPA06015096 A MX PA06015096A MX PA06015096 A MXPA06015096 A MX PA06015096A MX PA06015096 A MXPA06015096 A MX PA06015096A MX PA06015096 A MXPA06015096 A MX PA06015096A
Authority
MX
Mexico
Prior art keywords
methods
compositions
neurodegenerative
treating neurological
neurological disorders
Prior art date
Application number
MXPA06015096A
Other languages
English (en)
Inventor
Dan Frenkel
Ruth Maron
David Burt
Howard L Weiner
Original Assignee
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec
Publication of MXPA06015096A publication Critical patent/MXPA06015096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones utiles para el tratamiento de trastornos neurologicos, que incluyen trastornos neurodegenerativos asociados con la agregacion deleterea de proteinas, plegamiento aberrante de proteinas, tales como enfermedades amilogenicas del cerebro, y/o trastornos autoinmunes neurodegenerativos; se describen tambien metodos de uso de dichas composiciones; en particulas, se contemplan metodos para tratar un trastorno neurodegenerativo tal como enfermedad de Alzheimer y un trastorno autoinmune neurodegenerativo tal como esclerosis multiple, usando proteosomas y/o acetato de glatiramer, en donde el GA esta en una emulsion en submicras o una nanoemulsion.
MXPA06015096A 2004-06-25 2005-06-27 Composiciones y metodos para el tratamiento de trastornos neurologicos. MXPA06015096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58299904P 2004-06-25 2004-06-25
PCT/US2005/022922 WO2006004749A2 (en) 2004-06-25 2005-06-27 Compositions and methods for treating neurological disorders

Publications (1)

Publication Number Publication Date
MXPA06015096A true MXPA06015096A (es) 2007-05-09

Family

ID=35207559

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06015096A MXPA06015096A (es) 2004-06-25 2005-06-27 Composiciones y metodos para el tratamiento de trastornos neurologicos.

Country Status (18)

Country Link
US (1) US20060229233A1 (es)
EP (3) EP1761276B1 (es)
JP (2) JP5274011B2 (es)
KR (2) KR101347562B1 (es)
CN (2) CN103143011A (es)
AU (1) AU2005259991B2 (es)
CA (1) CA2571035A1 (es)
ES (1) ES2432369T3 (es)
HK (1) HK1101140A1 (es)
IL (1) IL179933A (es)
MA (1) MA28975B1 (es)
MX (1) MXPA06015096A (es)
NO (1) NO20070460L (es)
NZ (2) NZ578727A (es)
RU (2) RU2387453C2 (es)
SG (2) SG153871A1 (es)
WO (1) WO2006004749A2 (es)
ZA (1) ZA200610661B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004027940D1 (de) * 2003-10-22 2010-08-12 Id Biomedical Corp Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP2345412A1 (en) * 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
US7629135B2 (en) * 2006-12-22 2009-12-08 The Board Of Trustees Of The University Of Illinois Toll-like receptor agonists and antagonists and methods of use thereof
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
AU2008307565A1 (en) * 2007-10-01 2009-04-09 The Johns Hopkins University Methods of treating neurological autoimmune disorders with cyclophosphamide
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
WO2009132244A1 (en) * 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Methods for preparing immunogenic compositions
EP2299812B1 (en) * 2008-05-27 2017-07-12 Yale University Targeting tgf-beta as a therapy for alzheimer's disease
KR20120090044A (ko) * 2009-08-20 2012-08-16 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 낮은 빈도의 글라티라머 아세테이트 치료법
MX2012010634A (es) 2010-03-31 2012-11-29 Thomson Licensing Reproduccion trucada de datos de video.
WO2012058381A2 (en) 2010-10-27 2012-05-03 The General Hospital Corporation Apparatus, systems and methods for measuring blood pressure within at least one vessel
CA2851510A1 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
WO2017201539A1 (en) 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
RU2629385C1 (ru) * 2016-09-29 2017-08-29 Владимир Федорович Корсун Способ лечения рассеянного склероза
GB201916185D0 (en) * 2019-11-07 2019-12-25 Randox Laboratories Ltd Biomarker of drug-induced cellular toxicity and depression

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
BR9506885A (pt) * 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
WO1997010844A1 (en) * 1995-09-18 1997-03-27 United States Army Medical Research Materiel Command (Usamrmc) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
JP2000154148A (ja) * 1998-11-20 2000-06-06 Toray Ind Inc インターフェロンβをアジュバントとするワクチン
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
ES2344189T3 (es) * 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
CN100360180C (zh) 2000-01-20 2008-01-09 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
ATE331530T1 (de) * 2000-02-15 2006-07-15 Id Biomedical Corp Quebec Proteasom-influenzavirus-impfstoffzusammensetzu g
AU3846901A (en) * 2000-02-18 2001-08-27 Yeda Res & Dev Oral, nasal and pulmonary dosage formualtions of copolymer 1
KR100879810B1 (ko) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
DE60238471D1 (de) * 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
DE602004027940D1 (de) * 2003-10-22 2010-08-12 Id Biomedical Corp Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe

Also Published As

Publication number Publication date
JP2008504299A (ja) 2008-02-14
RU2007102698A (ru) 2008-07-27
CN101039691A (zh) 2007-09-19
JP5274011B2 (ja) 2013-08-28
HK1101140A1 (en) 2007-10-12
CA2571035A1 (en) 2006-01-12
RU2010103240A (ru) 2011-08-10
NZ578727A (en) 2011-03-31
US20060229233A1 (en) 2006-10-12
CN101039691B (zh) 2013-07-31
EP1761276B1 (en) 2013-07-24
NZ552075A (en) 2009-08-28
AU2005259991B2 (en) 2011-05-26
WO2006004749A3 (en) 2006-04-20
EP2332569A2 (en) 2011-06-15
KR20120112885A (ko) 2012-10-11
MA28975B1 (fr) 2007-11-01
EP2332570A1 (en) 2011-06-15
KR20070048703A (ko) 2007-05-09
SG153871A1 (en) 2009-07-29
WO2006004749A2 (en) 2006-01-12
IL179933A (en) 2015-06-30
IL179933A0 (en) 2007-05-15
KR101347562B1 (ko) 2014-01-03
EP1761276A2 (en) 2007-03-14
AU2005259991A1 (en) 2006-01-12
JP2012041351A (ja) 2012-03-01
ZA200610661B (en) 2008-08-27
CN103143011A (zh) 2013-06-12
NO20070460L (no) 2007-03-23
EP2332569A3 (en) 2011-09-14
ES2432369T3 (es) 2013-12-03
RU2387453C2 (ru) 2010-04-27
KR101347105B1 (ko) 2014-01-02
SG186686A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
MXPA06015096A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
WO2004110389A3 (en) Sigma ligands for neuronal regeneration and functional recovery
MY144612A (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
WO2008002933A3 (en) Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
IL220065A0 (en) Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
WO1995018616A3 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
WO2007035722A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
WO2004028468A3 (en) Methods and compositions for treatment of neurological disorder
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
AR043252A1 (es) Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica
MX2022008953A (es) Factores de transcripcion de proteina de dedos de zinc para reprimir la expresion de tau.
BRPI0512551A (pt) composições e métodos para tratar distúrbios neurológicos
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
MX2024006135A (es) Compuestos cannabinoides sinteticos, composiciones farmaceuticas, y metodos de tratamiento.
WO2000001440A3 (en) Methods for treating neurological injuries and disorders
TH169761A (th) องค์ประกอบนิวคลีเอสที่รักษาโรคและวิธีการ
WO2006108128A3 (en) Ocular delivery of interferon-tau

Legal Events

Date Code Title Description
FG Grant or registration